CAMK2D:一种新的分子点,用于BAP1缺乏的恶性间皮瘤
Sivasundaram Karnan1, Akinobu Ota2,3, Hideki Murakami4
1Department of Biochemistry, , Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. skarnan@aichi-med-u.ac.jp.
Cell death discovery
|July 21, 2023
概括
研究人员确定了恶性间皮瘤 (MMe) 的新治疗点. 用KN-93向/芽素依赖蛋白激酶II型子单元delta (CAMK2D) 基因,显示出治疗BAP1缺乏MMe.Me.的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 恶性间皮瘤 (MMe) 是一种罕见的,具有不良预后的侵袭性癌症.
- 虽然在MMe中已知BAP1基因变异,但缺乏有效的向疗法.
研究的目的:
- 开发针对BAP1缺乏MMe的分子向治疗方法.
- 根据MMe遗传变异确定新的诊断和治疗点.
主要方法:
- 生成的BAP1淘汰赛 (BAP1-KO) 人类中皮细胞克隆.
- 使用cDNA微阵列和qRT-PCR来分析基因表达.
- 对抗癌症药物库的BAP1-KO细胞进行了选.
- 在老鼠异种移植模型中评估药物疗效.
主要成果:
- 在BAP1-KO细胞中确定了高表达的/卡尔莫杜林依赖蛋白激酶II型子单元delta (CAMK2D).
- 在70%的MMe组织中,CAMK2D的表达很高,与BAP1损失相关.
- 鉴定了KN-93,一种CaMKII抑制剂,对BAP1缺乏的MMe细胞具有强大的抗增殖作用.
- 在体内,KN-93抑制了瘤生长.
结论:
- CAMK2D是BAP1缺乏MMe的潜在诊断和治疗目标.
- KN-93显示了BAP1缺乏MMe的显著治疗潜力.
- 这项研究提出了第一个针对BAP1缺乏MMe.Me的分子向治疗方法.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K


